Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINEPSAN Study
2018-001215-69Phase 3Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone and rituximab in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Relapse-free survival at Month 30. Started Jul 2018; status: active.
02
Drugs
prednisonerituximab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2018-001215-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001215-69.